Unknown

Dataset Information

0

Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration.


ABSTRACT: UNLABELLED:Drug delivery to atherosclerotic plaques via liposomal nanoparticles may improve therapeutic agents' risk-benefit ratios. Our paper details the first clinical studies of a liposomal nanoparticle encapsulating prednisolone (LN-PLP) in atherosclerosis. First, PLP's liposomal encapsulation improved its pharmacokinetic profile in humans (n=13) as attested by an increased plasma half-life of 63h (LN-PLP 1.5mg/kg). Second, intravenously infused LN-PLP appeared in 75% of the macrophages isolated from iliofemoral plaques of patients (n=14) referred for vascular surgery in a randomized, placebo-controlled trial. LN-PLP treatment did however not reduce arterial wall permeability or inflammation in patients with atherosclerotic disease (n=30), as assessed by multimodal imaging in a subsequent randomized, placebo-controlled study. In conclusion, we successfully delivered a long-circulating nanoparticle to atherosclerotic plaque macrophages in patients, whereas prednisolone accumulation in atherosclerotic lesions had no anti-inflammatory effect. Nonetheless, the present study provides guidance for development and imaging-assisted evaluation of future nanomedicine in atherosclerosis. FROM THE CLINICAL EDITOR:In this study, the authors undertook the first clinical trial using long-circulating liposomal nanoparticle encapsulating prednisolone in patients with atherosclerosis, based on previous animal studies. Despite little evidence of anti-inflammatory effect, the results have provided a starting point for future development of nanomedicine in cardiovascular diseases.

SUBMITTER: van der Valk FM 

PROVIDER: S-EPMC4625798 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications


Drug delivery to atherosclerotic plaques via liposomal nanoparticles may improve therapeutic agents' risk-benefit ratios. Our paper details the first clinical studies of a liposomal nanoparticle encapsulating prednisolone (LN-PLP) in atherosclerosis. First, PLP's liposomal encapsulation improved its pharmacokinetic profile in humans (n=13) as attested by an increased plasma half-life of 63h (LN-PLP 1.5mg/kg). Second, intravenously infused LN-PLP appeared in 75% of the macrophages isolated from i  ...[more]

Similar Datasets

| S-EPMC6343835 | biostudies-literature
| S-EPMC1829492 | biostudies-literature
| S-EPMC5557569 | biostudies-literature
| S-EPMC4883656 | biostudies-literature
2010-05-16 | E-GEOD-18275 | biostudies-arrayexpress
2009-12-30 | GSE18275 | GEO
| S-EPMC8478070 | biostudies-literature
| S-EPMC9160374 | biostudies-literature
| S-EPMC8137840 | biostudies-literature
| S-EPMC3787062 | biostudies-literature